Raptor Pharmaceutical Inc. (RPTP) Announces EMA Validation of Marketing Authorization Application for RP103 for the Treatment of Nephropathic Cystinosis
3/26/2012 10:24:15 AM
NOVATO, Calif., March 26, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced that the European Medicines Agency ("EMA") has determined that Raptor's Marketing Authorization Application ("MAA") for its investigational drug candidate, RP103 for the potential treatment of nephropathic cystinosis, submitted earlier this month, is valid. Validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process.
comments powered by